Atopic dermatitis represents one of the most prevalent manifestations of atopy in children, which is distinguished by the early onset and high frequency of chronicity. The aim of this study was to study the clinical features of atopic dermatitis in early childhood and to evaluate comorbid conditions. The prospective research was conducted to study the cohort of 68 patients, who were developed the atopic dermatitis under 2 years of age. It was revealed, that the age of onset of the disease and the clinical severity was determined by the genetic predisposition on the mother's side. According to the clinical severity of the disease there were revealed the series of peculiarities especially in the case of moderate course: the high frequency of comorbid allergic pathology (rhinitis, conjunctivitis, urticaria, allergic gastritis) and the co-existing gastroenterological disorders (colic, constipation and foaming). The use of CoMISSas a non-invasive tool assumes the great importance in respect of making timely diagnosis of the allergy to cow's milk protein.
Download full-text PDF |
Source |
---|
J Am Acad Dermatol
January 2025
Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA; Dermatology Service, US Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora, CO, USA; Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, MN, USA. Electronic address:
J Invest Dermatol
January 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Electronic address:
Contact hypersensitivity (CHS) and atopic dermatitis (AD) are pervasive inflammatory skin diseases with similar symptoms, and the global prevalence of both conditions is steadily rising. Many compounds and biotics have been developed to target molecules critical to the etiology or pathogenesis of CHS and AD. However, such molecules are sometimes ineffective or lose potency over the therapeutic course.
View Article and Find Full Text PDFBr J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDFDermatologie (Heidelb)
January 2025
Psychoneuroimmunologie Labor, Klinik für Psychosomatik und Psychotherapie, Justus-Liebig-Universität Gießen, Aulweg 123, 35385, Gießen, Deutschland.
Background: Atopic dermatitis is perhaps the most comprehensively studied skin disease in psychosomatic medicine and psychoneuroimmunology. Its biopsychosocial conceptualization incorporates psychodynamic as well as behavioral and systemic considerations. At the same time, there is also extensive biological knowledge of the neuroendocrine-immune control of barrier and immune function, characterized through animal experiments and translational clinical studies.
View Article and Find Full Text PDFACS Nano
January 2025
College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients' quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!